Glenmark Pharmaceuticals Limited — Q4 FY25
Glenmark's Q4 FY25 consolidated revenue grew 6.3% YoY to INR 3,256 crore, with full-year revenue up 12.8% to INR 13,322 crore.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY25
India business to achieve 9-10% growth for FY25
Management reiterated guidance of INR 1,100 crore per quarter average, implying 9-10% YoY growth for the full year.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1